Log In Sign up
The largest database of trusted experimental protocols

Sureselect human all exome v6

Manufactured by Agilent Technologies
Visit Supplier

The SureSelect Human All Exome V6 is a targeted sequencing solution designed for the capture and enrichment of the human exome. It covers the protein-coding regions of the genome, enabling efficient and comprehensive analysis of genetic variations.

Automatically generated - may contain errors

Lab products found in correlation

Agilent bioanalyzer 2100 system, by Agilent Technologies (1 mentions) Dna nano 6000 assay kit, by Agilent Technologies (1 mentions) Novaseq 6000, by Illumina (1 mentions) Hiseq 1500 2500, by Illumina (1 mentions)

Spelling variants of this product

Agilent SureSelect Human All Exome V6 kit (6 citations) Agilent SureSelect Human All Exome V6 (2 citations) SureSelect Human All Exome V6 kit (2 citations)

3 protocols using sureselect human all exome v6

1

Exome Sequencing of Low Tumor Cellularity

Check if the same lab product or an alternative is used in the 5 most similar protocols
A total of 1.0 µg of DNA per sample was used as input material for library preparation. Genomic DNA was sonicated to a size of 350 bp, and then fragments were end-polished, A-tailed, and ligated with the full-length adapter for Illumina sequencing with further PCR amplification. At last, PCR products were purified (AMPure XP system) and libraries were analyzed for size distribution using the DNA Nano 6000 Assay Kit of Agilent Bioanalyzer 2100 system (Agilent Technologies, CA, USA) and quantified using real-time PCR. The Agilent SureSelect Human All Exome V6 was used to capture exome regions. A total of five samples, with low tumor cellularity (< 60%), were sequenced using a panel of 484 cancer-related genes (CGP; Cancer Gene Panel) generated by xGen™ Custom Hybridization Capture Panels (Integrated DNA Technologies, CA, USA). The DNA sequencing produced paired-end reads of 150 bp.
Capasso M., Brignole C., Lasorsa V.A., Bensa V., Cantalupo S., Sebastiani E., Quattrone A., Ciampi E., Avitabile M., Sementa A.R., Mazzocco K., Cafferata B., Gaggero G., Vellone V.G., Cilli M., Calarco E., Giusto E., Perri P., Aveic S., Fruci D., Tondo A., Luksch R., Mura R., Rabusin M., De Leonardis F., Cellini M., Coccia P., Iolascon A., Corrias M.V., Conte M., Garaventa A., Amoroso L., Ponzoni M, & Pastorino F. (2024). From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models. Journal of Translational Medicine, 22, 151.
+ Open protocol
+ Expand
2

Whole Exome Sequencing of Colo205 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA was extracted from Colo205 cells isolated from endpoints of two competition experiments conducted in 100nM vemurafenib. Additionally, genomic DNA was extracted from two samples of parental Colo205 cells and parental Colo205 cells treated for 48-hours with 2μM AZ-3146. These genomic DNA samples were sent to Novogene Corporation Inc. for whole exome sequencing and analysis. In short, genomic DNA was fragmented by sonication, adaptors ligated, and fragments amplified by PCR. Fragment libraries were then hybridized with biotinylated probes (Agilent SureSelect Human All Exome V6) and pulled down with streptomycin-coated magnetic beads to enrich for exonic fragments. Captured fragment libraries were then amplified and index tagged in a PCR reaction followed by purification by AMPure XP beads. Libraries were sequenced on the Illumina NovaSeq 6000 platform. Sequences were aligned using BWA, Samtools, and Picard. SNP/InDel detection performed with GATK, MuTect, Strelka.
Lukow D.A., Sausville E.L., Suri P., Chunduri N.K., Wieland A., Leu J., Smith J.C., Girish V., Kumar A.A., Kendall J., Wang Z., Storchova Z, & Sheltzer J.M. (2021). Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. Developmental cell, 56(17), 2427-2439.e4.
+ Open protocol
+ Expand
3

Exome Sequencing Identifies ITGB3 Variant

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA was obtained from the three affected family members (i2, ii2, and ii3 in Fig 1A ) anda non-affected member (ii1 in Fig 1A ) in the pedigree. Whole exome sequencing (WES) was performed by HiSeq1500/2500 (Illumina, San Diego, CA) using SureSelect -Human ALL ExomeV6 (Agilent Technologies, Santa Clara, CA). The ITGB3 gene was amplified using the primer set 5'-CTCCTGCTTCTTCACAACC-3' and 5'-GGTCTGAGACTCTTAAGTGGAAG-3'. The identified ITGB3 p.T720del variatnt was confirmed by direct sequencing using the primer 5'-CTCCTGCTTCTTCACAACC-3'.
Miyashita N., Onozawa M., Hayasaka K., Yamada T., Migita O., Hata K., Okada K., Goto H., Nakagawa M., Hashimoto D., Kahata K., Kondo T., Kunishima S, & Teshima T. (2018). A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction. Annals of hematology, 97(4).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!